Fig. 4: NO depletion or NOS2-silencing increase the antitumoral efficacy of antihormonal treatment with tamoxifen. | Laboratory Investigation

Fig. 4: NO depletion or NOS2-silencing increase the antitumoral efficacy of antihormonal treatment with tamoxifen.

From: Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells

Fig. 4

a Breast cancer cells were treated with c-PTIO (60 μM for MCF-7 and 40 μM for MDA-MB-361 and BT-474) and/or 4-Hydroxytamoxifen (4HT, 0.05 μM for MCF-7 and 0.1 μM for MDA-MB-361 and BT-474). Cell proliferation was determined after 96 h of treatment using the incuCyte ZOOM Software. b Cell proliferation of shRNA-control and shRNA-NOS2 MCF-7 cells treated with different concentrations of 4HT during 96 h. c Representative images and percentage of mammospheres formed by shRNA-control and shRNA-NOS2 MCF-7 cells pre-treated for 24 h with different concentrations of 4HT. Scale bars: 50 μm. d Immunoblot analysis of Notch-1 protein expression levels in shRNA-control and shRNA-NOS2 MCF-7 cells treated with different concentrations of 4HT during 24 h. Stain-free technology was used as loading control. Data are means ± SEM of three independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001 compared with control).

Back to article page